ZA200906129B - Compounds for the treatment of hepatitis c - Google Patents

Compounds for the treatment of hepatitis c

Info

Publication number
ZA200906129B
ZA200906129B ZA2009/06129A ZA200906129A ZA200906129B ZA 200906129 B ZA200906129 B ZA 200906129B ZA 2009/06129 A ZA2009/06129 A ZA 2009/06129A ZA 200906129 A ZA200906129 A ZA 200906129A ZA 200906129 B ZA200906129 B ZA 200906129B
Authority
ZA
South Africa
Prior art keywords
hepatitis
compounds
treatment
Prior art date
Application number
ZA2009/06129A
Other languages
English (en)
Inventor
Robert G Gentles
Xiaofan Zheng
Min Ding
Yong Tu
Ying Han
Piyasena Hewawasam
John F Kadow
John A Bender
Kap-Sun Yeung
Katharine A Grant-Young
Thomas W Hudyma
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA200906129B publication Critical patent/ZA200906129B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
ZA2009/06129A 2007-03-14 2009-09-03 Compounds for the treatment of hepatitis c ZA200906129B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89488707P 2007-03-14 2007-03-14
US98947407P 2007-11-21 2007-11-21
PCT/US2008/055893 WO2008112473A1 (en) 2007-03-14 2008-03-05 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
ZA200906129B true ZA200906129B (en) 2010-11-24

Family

ID=39477552

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/06129A ZA200906129B (en) 2007-03-14 2009-09-03 Compounds for the treatment of hepatitis c

Country Status (19)

Country Link
US (1) US7547690B2 (cg-RX-API-DMAC7.html)
EP (1) EP2118109B1 (cg-RX-API-DMAC7.html)
JP (1) JP5232178B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100015304A (cg-RX-API-DMAC7.html)
CN (1) CN101657455B (cg-RX-API-DMAC7.html)
AR (1) AR065772A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008226639B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808763A2 (cg-RX-API-DMAC7.html)
CA (1) CA2681093A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000751A1 (cg-RX-API-DMAC7.html)
CO (1) CO6180426A2 (cg-RX-API-DMAC7.html)
EA (1) EA016614B1 (cg-RX-API-DMAC7.html)
IL (1) IL200905A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009009473A (cg-RX-API-DMAC7.html)
NZ (1) NZ579342A (cg-RX-API-DMAC7.html)
PE (1) PE20090648A1 (cg-RX-API-DMAC7.html)
TW (1) TW200848058A (cg-RX-API-DMAC7.html)
WO (1) WO2008112473A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906129B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 ５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
MX2010005226A (es) * 2007-11-20 2010-05-27 Bristol Myers Squibb Co Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
PL2238142T3 (pl) 2007-12-24 2012-11-30 Janssen R&D Ireland Makrocykliczne indole jako inhibitory wirusa zapalenia wątroby typu C
AU2009228337A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2268643B1 (en) * 2008-03-27 2014-08-06 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
PH12012501068A1 (en) * 2009-12-07 2013-02-04 Targacept Inc 3,6-diazabicyclo [3.1.1] heptanes as neuronal nicotinic acetylcholine receptor ligands
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
BR112015000714A2 (pt) * 2012-07-18 2017-06-27 Bristol Myers Squibb Holdings Ireland processos e intermediários para a preparação de (4bs,5ar)-12-ciclo-hexil-n-(n,n-dimetilsulfamoil)-3-metóxi-5a-((1r,5s)-3-metil-3,8-diazabiciclo[3.2.1]octano-8-carbonil)-4b,5,5a, 6-tetra-hidrobenzo [3,4]ciclopropa[5,6]azepino[1,2-a] indol-9-carboxamida
KR20180125960A (ko) 2016-03-15 2018-11-26 바이엘 크롭사이언스 악티엔게젤샤프트 동물 해충을 방제하기 위한 치환된 술포닐 아미드
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110028510A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法
CN114641467A (zh) 2019-11-07 2022-06-17 拜耳公司 用于防治动物有害物的取代的磺酰胺
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585113A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
JP5232178B2 (ja) 2013-07-10
EA016614B1 (ru) 2012-06-29
MX2009009473A (es) 2009-09-15
TW200848058A (en) 2008-12-16
AU2008226639B2 (en) 2012-07-19
EA200901241A1 (ru) 2010-02-26
IL200905A0 (en) 2010-05-17
AR065772A1 (es) 2009-07-01
US20080227769A1 (en) 2008-09-18
NZ579342A (en) 2011-07-29
EP2118109A1 (en) 2009-11-18
KR20100015304A (ko) 2010-02-12
CN101657455B (zh) 2013-02-06
CL2008000751A1 (es) 2008-07-25
EP2118109B1 (en) 2014-11-26
PE20090648A1 (es) 2009-05-29
AU2008226639A1 (en) 2008-09-18
BRPI0808763A2 (pt) 2014-09-16
CA2681093A1 (en) 2008-09-18
WO2008112473A1 (en) 2008-09-18
US7547690B2 (en) 2009-06-16
JP2010521476A (ja) 2010-06-24
CO6180426A2 (es) 2010-07-19
CN101657455A (zh) 2010-02-24

Similar Documents

Publication Publication Date Title
ZA200906129B (en) Compounds for the treatment of hepatitis c
ZA201105720B (en) Compounds for the treatment of hepatitis c
SI2209784T1 (sl) Spojine za zdravljenje hepatitisa C
ZA201000923B (en) Compounds for the treatment of hepatitis c
PT2303021T (pt) Compostos para tratamento do cancro
SI2001892T1 (sl) Spojine imidazolotiazol za zdravljenje proliferacijskih bolezni
ZA201006367B (en) Oxadiazoanthracene compounds for the treatment of diabetes
ZA200906210B (en) 3-Imidazolyl-Indoles for the treatment of proliferative diseases
ZA200907191B (en) Process for the preparation of gefitiib
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
ZA201001546B (en) Isoxazole compounds for the treatment of cancer
PL2285780T3 (pl) Sposoby i związki do wytwarzania normorfinanów
HK1138846A (en) Compounds for the treatment of hepatitis c
HK1133007A (zh) 治療丙型肝炎的化合物
HK1152310A (en) Compounds for the treatment of hepatitis c
GB0717139D0 (en) Treatment of hepatitis C
TH0801003323A (th) สารประกอบสำหรับการบำบัดโรคตับอักเสบ c
GB0602857D0 (en) The treatment of sialorrhoea
GB0617310D0 (en) Treatment of hepatitis c
GB0719613D0 (en) The treatment of pruritis
GB0814997D0 (en) Processes for the preparation of compounds